Rami G Azrak

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. pmc Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients
    Ali Ghadersohi
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Int J Cancer 123:1376-84. 2008
  2. pmc Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
    Cancer Lett 311:219-29. 2011
  3. ncbi request reprint Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Biol Ther 7:1901-8. 2008
  4. pmc Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States
    Biochem Pharmacol 73:1280-7. 2007
  5. pmc The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 5:2540-8. 2006
  6. ncbi request reprint Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression
    Ming biao Yin
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Pharmacol 66:153-60. 2004
  7. ncbi request reprint Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 4:843-54. 2005
  8. ncbi request reprint Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts
    Rami G Azrak
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Clin Cancer Res 10:1121-9. 2004
  9. ncbi request reprint A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 12:1237-44. 2006
  10. pmc Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers
    Maher S Saifo
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Mol Cancer 9:310. 2010

Detail Information

Publications12

  1. pmc Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients
    Ali Ghadersohi
    Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Int J Cancer 123:1376-84. 2008
    ....
  2. pmc Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
    Cancer Lett 311:219-29. 2011
    ..The finding is of clinical relevance for enabling the delivery of higher doses of irinotecan to reverse tumor resistance, recurrence and ultimately enhancing cure rates...
  3. ncbi request reprint Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Biol Ther 7:1901-8. 2008
    ..In conclusion, these data suggest that synergy between MSeA and paclitaxel in skov3 is associated with silencing survivin expression...
  4. pmc Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States
    Biochem Pharmacol 73:1280-7. 2007
    ..Intratumoral total Se concentration was not found to be predictive of the combination therapy response rates. There is a critical need to develop a method to measure the active metabolite of MSC, rather than total Se...
  5. pmc The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 5:2540-8. 2006
    ..The synergy between MSeC and docetaxel in C2G prostate cancer cells is associated with increased level of caspase-dependent apoptosis and decreased level of survivin...
  6. ncbi request reprint Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression
    Ming biao Yin
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Pharmacol 66:153-60. 2004
    ....
  7. ncbi request reprint Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors
    Rami G Azrak
    Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 4:843-54. 2005
    ..No correlation was observed between cure rate and other investigated variables (transporters, degradation enzymes, DNA repair, and cell survival/death genes) in either tumor...
  8. ncbi request reprint Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts
    Rami G Azrak
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Clin Cancer Res 10:1121-9. 2004
    ..Studies were carried out to define the optimal dosage, sequence, and timing for the combination in mice bearing xenografted human tumors...
  9. ncbi request reprint A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 12:1237-44. 2006
    ..We conducted a phase I study to determine the maximum tolerated dose (MTD) of irinotecan with fixed, nontoxic high dose of selenomethionine...
  10. pmc Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers
    Maher S Saifo
    Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Mol Cancer 9:310. 2010
    ....
  11. pmc Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer
    Ali Ghadersohi
    Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics, Buffalo, New York, USA
    Prostate 71:1178-88. 2011
    ..However, the clinical relevance of PDEF expression and its relationship to anti-apoptotic protein survivin is yet to be determined...
  12. ncbi request reprint Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350
    Ming biao Yin
    Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Biochem Biophys Res Commun 295:435-44. 2002
    ..The data indicate that the chk1 signaling pathways that mediate cell cycle checkpoint are associated with cellular resistance to BNP1350 in the A253/BNPR cell line...